KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBT (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of EBT data on record, last reported at $1.0 billion in Q4 2025.

  • For Q4 2025, EBT rose 8.93% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $5.2 billion, up 9.43%, while the annual FY2025 figure was $5.2 billion, 9.43% up from the prior year.
  • EBT reached $1.0 billion in Q4 2025 per REGN's latest filing, down from $1.8 billion in the prior quarter.
  • Across five years, EBT topped out at $3.8 billion in Q2 2021 and bottomed at -$2.0 billion in Q4 2022.
  • Average EBT over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2023.
  • Peak YoY movement for EBT: surged 308.4% in 2021, then plummeted 74.33% in 2022.
  • A 5-year view of EBT shows it stood at $1.8 billion in 2021, then tumbled by 208.09% to -$2.0 billion in 2022, then skyrocketed by 158.44% to $1.1 billion in 2023, then fell by 16.51% to $958.1 million in 2024, then grew by 8.93% to $1.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $1.0 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.5 billion in Q2 2025.